NGVTIngevity Corporation
Is the business good?
The checks split: nothing decisive, though margins widening.
Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is NGVT?
Ingevity Corporation keeps 4.7% of every revenue dollar as profit after everything, against 4.8% for the median Specialty Chemicals name.
Net margin · Specialty Chemicals median 4.8% · 12 months to Q2 2026
- Share count, year on year
- −3.2%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 2.3%
R&D as % of revenue
- Gross margin
- 41%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | 33% |
| FY2021 | 30% |
| FY2022 | 27% |
| FY2023 | 35% |
| FY2024 | 35% |
| FY2025 | 36% |
Details›
- Gross margin12 months to Q2 2026
- 41%
- Net margin12 months to Q2 2026
- 4.7%
- Free cash flow margin
- 13%
- R&D as % of revenue
- 2.3%
- Revenue, trailing twelve months
- $1.16B
- Free cash flow, trailing twelve months
- $155M
- Net income, trailing twelve months
- $54M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Specialty Chemicals
Ranks #5 of 33 by RyuScore